Inactive Instrument

Transgenomic Inc Stock Nasdaq

Equities

US89365K3059

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq
- USD - Intraday chart for Transgenomic Inc
Sales 2022 9.41M Sales 2023 15.2M Capitalization 9.23M
Net income 2022 -12M Net income 2023 -5M EV / Sales 2022 1.12 x
Net cash position 2022 2.05M Net cash position 2023 386K EV / Sales 2023 0.58 x
P/E ratio 2022
-1.03 x
P/E ratio 2023
-1.44 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 95.57%
More Fundamentals * Assessed data

Latest transcript on Transgenomic Inc

Managers TitleAgeSince
Chief Executive Officer 52 17-06-27
Director of Finance/CFO 57 17-06-30
Chief Tech/Sci/R&D Officer 39 -
Members of the board TitleAgeSince
Director/Board Member 64 21-02-28
Director/Board Member 62 18-08-08
Chairman 80 19-12-02
More insiders
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
More about the company